pharmaceuticals
| “They Only Silence the Truth”: COVID-19 retractions and the politicization of science |
| A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 |
| Canary in a (Post) Covid World: Money, Fear, and Power |
| Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients |
| Cardiac Findings in COVID-19 Patients Treated with HAZDPac |
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread |
| Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study |
| Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection |
| Covid-19 Has Turned Public Health Into a Lethal, Patient-Killing Experimental Endeavor |
| COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study |
| Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? |
| Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19) |
| Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients |
| Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis |
| Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France |
| HCQ for COVID-19: 412 studies from 8,590 scientists 529,060 patients in 58 countries |
| HCQ for COVID-19: real-time meta analysis of 368 studies |
| Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |
| Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients |
| Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials |
| In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |
| Ivermectin Could Have Saved Millions of Lives, Why Was It Suppressed |
| Largest Statistically Significant Study by 6,200 Multi-Country Physicians on COVID-19 Uncovers Treatment Patterns and Puts Pandemic in Context |
| Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic |
| Open Knowledge Commons versus Privatized Gain in a Fractured Information Ecology: Lessons from COVID-19 for the Future of Sustainability |
| Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients |
| Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities |
| Role of hydroxychloroquine in multidrug treatment of COVID-19 |
| The Key to Defeating COVID-19 Already Exists. We Need to Start Using It |
| The Worldwide Corona Crisis, Global Coup d’Etat Against Humanity |
| Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial |
| Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2 |
| VAERS deaths attributed to COVID-19 vaccines as of June 2021 |
| Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards |
| WHO advises that ivermectin only be used to treat COVID-19 within clinical trials |
